Vigil Neuroscience's Oral Alzheimer's Candidate VG-3927 Shows Promising Phase 1 Results with Sanofi's Strategic Support on January 28, 2025 Agonist Alzheimer 's disease Clinical Trials Microglia Phase 1 (qualifier value) Programs - Publication Format Sanofi Strategic TREM2 VG-3927 Vigil +